Zydus Lifesciences on Friday said it has received approval from the US health regulator for its new drug application for a diabetes medication. The company has received final approval for its new drug application (NDA) from the US Food and Drug Administration (USFDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets, the drug firm said in a statement.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/yHnmBzL
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment